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Background: Pain is a major health care problem for patients with cancer: despite the existence of guidelines for
cancer pain management, undertreatment is a widespread problem. Pain Management Indexes (PMIs) evaluate the
congruence between the patient’s reported level of pain and the intensity/strength of the analgesic therapy. Negative
scores indicate inadequate prescriptions.
Materials and methods: We conducted a Medline search using terms for ‘pain management’, ‘index’ or ‘measure’
to select studies which measured undertreatment in cancer settings. Univariate and multivariate logistic regression
identified associations between independent predictors and high prevalence of undertreatment.
Results: Among the 44 studies identified, 26 studies used the PMI as proposed by Cleeland. The range of negative
PMI varied from 8% to 82% with a weighted mean value of 43%. In multivariate analyses, factors associated with
negative PMI were date of publication before 2001, provenance from Europe or Asia and countries with a gross
national income per capita <$40 000 per year and a care setting not specific for cancer. Age was not a significant
predictor for undertreatment.
Conclusion: Nearly one of two patients with cancer pain is undertreated. The percentage is high, but consists of
a large variability of undertreatment across studies and settings.
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introduction
Pain is a major health care problem for patients with cancer [1]:
a recent meta-analysis reports that 64% of patients with
advanced stage disease or metastatic cancer will experience pain
[2]. Despite the diffusion of several guidelines for cancer pain
management, including well-known recommendations of the
World Health Organization (WHO) [3], the Agency for Health
Care Policy and Research (AHCPR) [4] and the Expert
Working Group of the European Association for the Palliative
Care [5] and even if effective treatments are available for 70%–
90% of cases [6], undertreatment is well documented and can
involve up to 40% of patients [7]. Undertreatment is usually
attributed to an inappropriate use of opioids for reasons often
conceptualized in terms of barriers related to health care
provider, patient, family, institution and society [8].
Several instruments have been created to investigate the
presence and grade of undertreatment [9–13]. The Pain
Management Index (PMI) is a well-validated method of
assessing the adequacy of pain control based on WHO and
AHCPR guidelines which was developed by Cleeland et al. [9]
for cancer patients in 1994. Pain management is considered
adequate if there is congruence between the patient’s reported
level of pain and the appropriateness of the analgesic therapy.
Operationally, patient’s worst pain intensity is related to the
pain medication as prescribed by the physician. Ward’s [10]
and Zelman’s [11] PMIs use Cleeland’s structure with slights
modifications: in Ward’s version, the worst pain intensity is
related to the pain medication as used by the patient; Zelman’s
version compares current, worst and average pain intensity to
the medication used [12]. Some authors have subsequently
modified Cleeland’s index to improve its validity and
sensitivity: Ward et al. [13] proposed a more complex index
(PMI-Revised) in order to take into account the patient’s least
pain scores as well. De Wit et al. [12] proposed a further
revision (Amsterdam PMI) in order to incorporate other
dimensions of pain experience: current and average pain
intensity, individual threshold of tolerability of pain,
noncompliance to the therapy prescribed and the whole pain
medication (including all opioids and non opioids) actually
taken by the patient.
The objectives of this work are (i) to identify and describe all
the studies conducted between 1987 and 2007 which assessed
re
v
ie
w
*Correspondence to: Dr S. Deandrea, Istituto di Ricerche Farmacologiche Mario Negri,
Via Giuseppe La Masa 19, 20156 Milan, Italy. Tel: +39-02-39014-653;
Fax: +39-02-33200231; E-mail: deandrea@marionegri.it
ª The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
 at Istituto M
ario N
egri on O
ctober 17, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
pain undertreatment using PMIs; (ii) to estimate the prevalence
of undertreatment in an homogeneous sample of cancer
patients using the most common index and (iii) to examine
whether a priori selected variables (i.e. location, disease stage)
could help in better understanding the epidemiology of the
phenomenon.
materials and methods
Studies were identified in Medline, by scanning references and through
consultation with experts in the field. The search strategy used the following
terms: ‘pain management’ AND (index OR measure). No limits were
applied for language. The search only included records from January 1987
through October 2007 because 1987 is the date Zelman et al. [11] first
presented data about the use of a PMI in cancer patients. We defined
the following eligibility criteria: (i) computation of PMI score for each
patient and (ii) reporting of the percentage of negative PMI in the study
sample. Our operational definition of PMI was ‘an index that subtracts
the patient’s rating of pain from the rating of the strongest analgesic agent’.
The eligibility assessment was carried out by a standardized manner by
one reviewer (SD). Details of study design, participants, disease, setting,
outcome assessors, PMI and methods to compute were recorded.
Information was extracted using a pro forma process piloted on
a random sample of papers. In order to select the most used index, the
different PMIs were ranked on the basis of the number of studies that
used them.
Finally, from the studies retrieved, we further selected only those which:
(i) computed PMI according to the most used index and (ii) investigated
pain in cancer patients, regardless of the care setting (i.e. cancer care ward
versus general medical ward).
Among the included papers, we also collected possible determinants of
a negative PMI that were referred by the authors of individual studies as
a possible predictor of a high prevalence of negative PMI.
We reported the frequency of the different determinants of each article.
Whenever there was sufficient variability, we analyzed that characteristic by
the direction of results to assess whether certain determinants were
associated with negative PMI. Moreover, some other epidemiological
factors have been hypothesized to be independently related to negative PMI,
mostly for economic, political and social reasons, such as differences
between high- and low-resource settings. All these potential predictors of
a high prevalence of negative PMI were investigated across studies. The
predictor variables considered were as follows:
 Year of publication as a proxy of year of study conduction because
several papers did not report this information. The papers were
divided between those published before 2001 (median year) and those
published in 2001 or after.
 Geographic area: this was split into Asia, Europe and North America.
Israel was included in Asia because of its continental location. South
Africa was the source of a single study, and it could not have been
assimilated to the other geographical categories.
 Economic level: we used the gross national income (GNI per capita)
converted in US dollars following the World Bank Atlas method divided
by the midyear population as a proxy of the country development level.
Data were extracted from the World Bank Data and Statistics [14]; they
were updated to 2006 for each country except for Israel, where data are
relative to 2005. Papers were classified into those coming from a country
with a GNI pro capita <$20 000, with a GNI between $20 000 and
$40 000 and with a GNI ‡$40 000.
 Setting in which the patients enrolled in the study were treated: this was
classified as specific for cancer patients (i.e. oncology hospitals and
wards, hospices), not specific (i.e. general wards, general practice) and
mixed.
 Stage of the disease: this was estimated by classifying the papers
according to the percentage of patients in the sample with metastatic or
advanced disease, when available, and adopting the mean value (68.8%)
as a cut-off.
 Age of patients: this was estimated considering the mean age of the
sample for each article (median when the mean age was not provided)
and was classified in two levels using the median across papers (57.5
years) as a cut-off.
Finally, the range of negative PMIs, standard deviation, median and mean
weighted by sample size for the whole study pool and for subgroups
described were computed. Multivariable logistic regression analysis was
used to describe the relationship between the response variable (each study
was classified into one of two mutually exclusive levels according to the
level of undertreatment: 0 if PMI ‡51% and 1 if PMI <51%) and a list of
potential explanatory variables (year of publication, geographical area,
economic level and setting of care). All selected variables were weighted for
study sample size and for this analysis geographical area and economic
level were dichotomized into non-USA versus USA and <$40 000
versus ‡$40 000 to evaluate the association with respect to the best
category found at the descriptive step. Each variable was controlled for
all the others included in the model.
results
The search of Medline produced 1115 citations; on a first sift,
453 citations were immediately discharged being irrelevant for
that issue; review of the titles and abstracts of the remaining 662
papers, integrated by scanning the references and consulting the
experts in the field, yielded 46 relevant articles [9–13, 15, 16,
18–41, Appendix]. An area of concern was the amount of
multiple publications for the Amsterdam PMI. The comparison
of different PMIs in the same patient group (313 Dutch cancer
patients) was published more than once [12, 15, 16]. We
selected the first publication computing PMI for that sample of
patients [15]. The main characteristics of the 44 original studies
are reported in Table 1. The majority of them (79.6%) chose to
define PMI as proposed by Cleeland et al. [9]; seven studies
(15.9%) computed Ward’s PMI [10] and two studies used
Zelman’s PMI [11] (4.6%). Three studies (6.8%) computed
more than one index in order to compare different measures of
pain management. A brief description of most used indexes is
presented in Box 1. The disease most frequently selected was
cancer (75%), followed by AIDS (11.4%).
Our final sample of 26 papers consisted of those that used the
PMI Cleeland in cancer patients [9, 15, 18–41]. A brief
description of studies included is reported in Table 2. Some
studies used PMI computation methods slightly different from
Cleeland’s original proposal [9], such as an alternative
categorization of pain level. These studies followed a different
classification of the pain experience proposed by Serlin in 1995
[17], in which pain scores of 1–4 correspond to mild pain, scores
of 5–6 to moderate pain and scores of 7 or greater to severe pain.
In 14 studies, the authors of the original papers tried to
recognize prognostic factors for undertreatment. The variables
most commonly considered are described in Table 3:
sociodemographic status (age, gender, race, education) [9, 15,
18–20, 24, 27, 32, 34–36], disease stage (presence of distant
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metastasis, performance status) [9, 18–20, 24, 27, 32, 34–36]
and pain characteristics (intensity, discrepancy between
physician’s and patient’s rating of pain severity) [9, 18, 20, 24,
32, 33, 35]. The results regarding the predictive role of age are
not consistent: five studies [19, 24, 27, 32, 36] found no
relation, three studies [9, 34, 35] reported that older patients
are treated worse than younger ones, but another study [18]
reported a significant favorable role played by advanced age.
Only two studies [15, 24] of 10 reported that being female is an
indicator of worse pain treatment. Patients who were rated less
ill (better PS) and at an early stage of the disease (no distant
metastasis) in more than half of the 10 studies which
considered these aspects were more likely to receive inadequate
analgesia. One [9] of two studies found that minority or less-
educated patients are more likely to be undertreated. The
discrepancy between the physician’s and patient’s estimate of
the severity of pain is an undertreatment predictor consistently
detected across studies (four of five).
Table 4 reports the range of negative PMIs, standard
deviation, median and mean weighted by sample size for the
whole study pool and for selected subgroups. The range of
negative PMIs varied from 8% to 82% with a weighted mean
value of 43%. The high values of standard deviations and pain
ranges indicate a high variability within and across subgroups.
After adjusting for the confounding effect of potential
covariates, year of publication, country (in terms of
geographical location and economic level) and setting showed
to be associated with the probability of a higher proportion of
PMI negative values. Socioeconomical variables appears to be
the strongest determinant for undertreatment, with
a multivariate odds ratio (OR) for European and Asian
countries of 7.26 [95% confidence interval (CI) 5.75–9.15]
versus United States and a multivariate OR for countries with
GNI <$40 000 of 5.84 (95% CI 5.03–6.79) versus countries with
GNI ‡$40 000 (Table 5). The multivariate OR for papers
published before 2001 versus papers published in 2001 or after
was 4.73 (95% CI 3.94–5.67).
discussion
Our analysis of 26 relevant studies showed that 43% of cancer
patients have a negative PMI score: nearly one of two patients is
undertreated. Such a percentage is exceedingly high, but
a temporal trend suggests a slight improvement in cancer pain
management throughout the years. It is likely that this
condition comes from a situation in progress due to better
medical education and greater attention paid by national and
international agencies such as WHO [42] and The Joint
Commission [43]. A geographical and economical trend
emerged as well in favor of the United States and other rich
countries. Wealthier health systems can sustain and encourage
a better pain management through pain control campaigns and
drug full covering by national health systems or health
insurances. The multivariate analyses also showed an
association between negative PMI and settings not specific for
cancer patients, maybe due to a lack of specific education in
pain management for physicians who have not specialized in
oncology or palliative care.
Once the percentage of undertreated patients using a pain
index was determined, several investigators tried to identify
prognostic factors. Gender and advanced age do not seem to
play a role consistently. Patients who were rated less ill (better
Performance Status) and at an early stage of the disease (no
distant metastasis) were more likely to receive inadequate
analgesia. A possible explanation is that patients who look less
ill may also be judged to have less pain [9, 44]. A different
interpretation of this result is that metastatic patients are
treated by a pain expert more frequently than patients at an
earlier stage of disease. The discrepancy between the physician’s
and patient’s estimate of the severity of pain experienced and
the potential role played by education and ethnicity can suggest
that a failure in physician–patient communication may also
play a role in undertreatment genesis.
Although PMI is not accurate for prescribing drugs for an
individual and not appropriate to evaluate quality of care at an
Table 1. Main characteristics of 44 original studies in terms of type of
PMI computed and patients’ disease
No. of studies (%)
Type of PMI computeda
PMI Cleelandb 35 (79.6)
PMI Wardc 7 (15.9)
PMI Zelmand 2 (4.6)
Diseasee
Cancer patients 33 (75.0)
AIDS patients 5 (11.4)
Other 7 (15.9)
aSome studies present more than one PMI type. In two studies it was not
possible to detect the type of PMI computed.
bComputed as analgesic prescribed 2 worst pain intensity.
cComputed as analgesic actually used 2 worst pain intensity.
dComputed as: analgesic actually used 2 [present pain intensity + average
pain intensity + worst pain intensity]/3.
eSome studies consider more than one category of patients’ disease.
PMI, Pain Management Index.
Box 1: Pain Management Indexes
Cleeland’s PMI is constructed upon the patient’s level of
worst pain on the Brief Pain Inventory categorized as
0 (no pain), 1 (1–3, mild pain), 2 (4–7, moderate pain), or
3 (8–10, severe pain). Then, the pain level is subtracted
from the most potent level of analgesic drug therapies as
prescribed by the physician, scored as 0 (no analgesic
drug), 1 (nonopioid), 2 (a weak opioid) or 3 (a strong
opioid). The index can range from 23 (a patient with
severe pain receiving no analgesic drug) to +3 (a patient
receiving strong opioids and reporting no pain). Negative
scores indicate inadequate orders for analgesic drugs, and
score of 0 and higher are considered indicators of
acceptable treatment.
Zelman’s PMI measures pain intensity as the mean
among present pain, average pain and worst pain.
Ward’s PMI considers the analgesic therapy actually
used by the patient instead of the physician’s prescription.
Annals of Oncology review
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individual level, it provides a rough estimate of how pain is
treated in the population. However, it does not take into
account other aspects of the complex problem of cancer
pain management: the patient’s compliance to the therapy [10],
the dosage [45] and route of administration of the most
potent analgesic prescribed, potential associations with
further analgesic adjuvant drugs (i.e. antidepressants,
anticonvulsants) and with other nonpharmacological therapies
(i.e. acupuncture, biofeedback). Also, the index takes into
account drugs recently prescribed but not yet taken, thus
patients with severe pain who were prescribed morphine at
the time of the survey are classified as adequately treated. Some
authors developed alternative indexes [10–13] just to
incorporate in the score some of these additional aspects.
When the PMI Cleeland, Ward and Zelman were compared
by de Wit et al. [15], the percentage of agreement was very
high, especially for Cleeland and Ward (kappa from 0.81 to
1.00), which suggests a broad overlap and a common structure
among these measures. The Amsterdam PMI, on the contrary,
showed only a fair agreement with the three PMIs [12],
meaning that it may give an estimate of pain treatment
adequacy different from the other three. Once these limitations
Table 2. Description of 26 original studies that report PMI Cleeland in cancer patients according to the year of publication, the country where the
investigation was conducted, the sample size and the percentage of negative PMI
Name of the first
author (reference)
Year
(publication)
Country No. of
patients
Percentage of
negative PMI (95%
confidence interval)a
Notes
Cleeland [9] 1994 United States 597 42 (38–46)
Larue [18] 1995 France 270 51 (45–57)
Wang [19] 1996 China 147 67 (59–75)
Cleeland [20] 1997 United States 197 65 (58–72) Minority outpatients with
recurrent or metastatic cancer
Elliott [21] 1997 United States 314 16b, 41b 16% for patients reporting pain in the
3 months before the interview, 41% for
patients reporting pain at the time of
the interview
Trowbridge [22] 1997 United States 320 38 (31–46), 35 (28–42) 38% in control group, 35% in
intervention group
Ger [23] 1998 Taiwan 113 69 (61–78)
Uki [24] 1998 Japan 121 27 (19–35)
Saxena [25] 1999 India 200 79 (73–85)
de Wit [15] 1999 The Netherlands 313 49 (43–55) Compares the three PMIs: PMI
Cleeland (48.9%), PMI Ward (55.1%),
PMI Zelman (35.9%)
Anderson [26] 2000 United States 108 31 (17–45); 28 (17–39) 31% for African-American
patients, 28% for Hispanic patients
Wells [27] 2000 United States 139 29 (22–37)
Mystakidou [28] 2001 Greece 220 76 (70–82)
Sabatowski [29] 2001 Germany 905 13 (11–15)
Beck [30] 2001 South Africa 426 31 (27–35)
Cascinu [31] 2003 Italy 117 43 (34–52) Uses a present pain intensity scale
Shvartzman [32] 2003 Israel 218 75 (69–81)
Hyun [33] 2003 Korea 508 41 (37–45)
Yun [34] 2004 Korea 132 74 (67–82) Computes PMI-Revised as well
Di Maio [35] 2004 Italy 752 82 (79–85) Non-small-cell lung cancer patients.
Uses the quality of life questionnaires
Okuyama [36] 2004 Japan 138 70 (62–78)
Cohen [37] 2005 Israel 39 56 (40–72)
Lin [38] 2005 United States 102 64 (55–73) Prison inmates
Passik [39] 2006 United States 100 8 (3–13) Considers also 73 AIDS patients (33%
has a negative score)
Russell [40] 2006 UK 864 7 (3–11), 9 (7–11) 7% for hospice patients, 9% for patients
treated by general practitioners. Uses
the Palliative Outcome Scale
Enting [41] 2007 The Netherlands 244 65 (59–71)
aComputed on the basis of the data reported in the paper.
bIt is not possible to compute 95% confidence interval because of some missing data.
PMI, Pain Management Index.
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are considered, PMI Cleeland can be used not to obtain a score
of any aspect related to pain management, but to find out the
consistency between the physician’s order and good practice
guidelines. The usefulness of this indicator is proved by the
great number of studies that have used this score since 1994,
and its application to medical conditions other than cancer,
particularly for AIDS.
Our study recognizes some limitations: some shortcomings
are related to the intrinsic characteristics of the instrument
used, whereas others are related to the impossibility of
excluding the existence of additional studies which used PMI
that were not published or not retrievable through Medline
with the search method used. Also, the attempt of identifying
variables predictive of better pain management, carried out on
a study level and not on an individual patient level, carries
significant risk of low sensitivity.
In addition, the large variability of undertreatment
prevalence across studies and settings maybe also related to
some hidden (not measured) variables that could not be taken
into account in our univariate and multivariate analyses
because they were not assessed by original authors and thus
not reported in the papers. This fact is suggested by the
results from an ongoing prospective study carried out in Italy
in 2007 [46, 47] where PMI Cleeland was prospectively
utilized to assess the prevalence of undertreatment in a cohort
of 1801 cancer patients seeking care in 110 Italian oncologic
and palliative centers. Overall, the prevalence of PMI negative
scores at the time of study inclusion was 25%, with large
variations according to several variables including patients,
centers and settings characteristics, such as presence of bone
metastasis, ongoing chemotherapy or adjuvant therapy and
type of recruiting centers (oncologic or palliative). The case-
mix of the cases recruited yielded a large variability across
subgroups, reaching a prevalence of up to 45% in some
subgroups.
In conclusion, PMI maybe useful in evaluating the quality of
the analgesic care in large sample cases. The proportion of
Table 3. Variables affecting PMI frequently investigated in studies
included
Variable No. of papers
that study this
variable
No. of papers that
find this variable
affecting PMI
Advanced age 9 4
Female gender 10 2
Race 2 1
Education 2 1
Performance status 9 4
Stage of the disease and/or
presence of metastasis
5 5
Pain intensity 2 2
Discrepancy between the pain
rate given by patient and
by the physician
5 4
PMI, Pain Management Index.
Table 4. Range of negative PMI, standard deviation, median and mean weighted by sample size for selected subgroups and for the whole study pool
Characteristics of studies No. of
studies
Range of negative
PMI (%)
Standard
deviation
Median Weighted
mean
Year
1994–2000 12 27–79 18.47 46.5 46.6
2001–2007 14 8–82 26.33 60.0 41.5
Geographic area
United States 8 8–65 19.14 33.0 39.1
Europe 8 9–82 26.62 51.0 40.3
Asia 9 27–79 17.47 69.0 59.1
Economic level
GNI per capita < $20 000 8 31–79 17.37 68.0 53.7
GNI per capita $20 000–$40 000 7 13–82 25.75 51.0 48.2
GNI per capita ‡$40 000 11 8–65 20.72 37.0 34.2
Settinga
Specific for cancer patients or hospiceb 15 8–79 21.33 53.5 52.2
Not specificb 5 29–74 23.45 46.5 42.8
Mixed 5 9–82 27.00 58.0 44.6
Stage of diseasea
At least 68.8% metastatic 8 13–65 16.54 39.5 31.2
<68.8% metastatic 12 29–82 17.75 66.0 58.4
Mean age of the samplea
‡58 years old 11 27–79 19.62 65.0 55.1
<57 years old 11 8–82 21.52 43.0 53.6
Total 26 8–82 22.63 51 43.40
aIn some of the studies included in the review this characteristic was not specified.
bPMI score extracted from Russel et al. has been splitted.
PMI, Pain Management Index.
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cancer patients whose pain is undertreated is still high, reaching
almost a half of all the patients considered in this review.
Variability of its occurrence in this sample of studies suggests
important pain determinants: geographical area (Europe and
Asia), countries with lower economic level and setting not
specific for cancer care and management. These results are
important for implementing policies to reduce inappropriate
high pain prevalence and to address barriers to pain control in
the neglected context.
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than cancer, PMI used not clear or different from Cleeland’s)
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patient and reported the percentage of negative PMI.
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2000; 19: 339–347.
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management outcomes for hospitalised Hispanic patients.
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42: 1239–1247.
12. Sherwood GD, McNeill JA, Starck PL, Disnard G.
Changing acute pain management outcomes in surgical
patients. AORN J. 2003; 77: 374, 377–380, 384–390 passim.
13. McNeill JA, Sherwood GD, Starck P. The hidden error of
mismanaged pain: a systems approach. J Pain Symptom
Manage 2004; 28: 47–58.
14. Strohbuecker B, Mayer H, Evers GC, Sabatowski R. Pain
prevalence in hospitalized patients in a German university
teaching hospital. J Pain Symptom Manage 2005; 29:
498–506.
15. van den Beuken-van Everdingen MH, de Rijke JM, Kessels
AG et al. High prevalence of pain in patients with cancer in
a large population-based study in The Netherlands. Pain
2007; 132: 312–320.
Table 5. Univariate and multivariate ORs and 95% CIs of negative PMI ‡51% according to selected variables
Characteristic Category Negative PMI ‡median (51%)
Studies
n/total n (%)
Univariate Multivariate
OR (95% CI) OR (95% CI)
Year 1994–2000 6/12 (50) 1.33 (0.28–6.28) 4.73 (3.94–5.67)*
2001–2006 8/14 (57) 1 1
Geographic area United States 2/8 (25) 1 1
Europe 5/8 (63) 5.00 (0.58–42.80) 7.26 (5.75–9.15)*
Asia 7/9 (78) 10.50 (1.11–98.91)
Economic level GNI per capita <$20 000 6/8 (75) 5.25 (0.70–39.48) 5.84 (5.03–6.79)*
GNI per capita $20 000 - $40,000 4/7 (57) 2.33 (0.34–16.18)
GNI per capita ‡$40 000 4/11 (36) 1 1
Setting Specific for cancer patients or hospicea 8/15 (53) 1 1
Not specifica 2/5 (40) 0.75 (0.08–6.96) 2.11 (1.68–2.65)*
Mixed 4/5 (80) 1.50 (0.20–11.09) 2.21 (1.92–2.55)*
Stage of disease At least 68.8% metastatic 2/8 (25) 1 Not included in the model
<68.8% metastatic 9/12 (75) 9.00 (1.14–71.04)
Mean age of the sample ‡58 years old 5/11 (45) 1 Not included in the model
<57 years old 8/11 (73) 3.20 (0.54–18.98)
aPMI score extracted from Russel et al. has been splitted.
*P < 0.0001.
OR, odds ratio; CI, confidence interval; PMI, Pain Management Index.
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